Most Schizophrenia Patients Open to Bimonthly Injection

In a five-country survey, most adults with schizophrenia preferred a once-every-2-months long-acting injection to daily tablets.

Updated on Nov. 3, 2026 in Autism

Single plain injection pen resting on a bare wooden surface beside a glass of water in a calm, uncluttered room.
Most adults with schizophrenia in a five-country survey said they would accept a long-acting antipsychotic injection given only once every two months rather than daily tablets. AI Illustration. Upload story photo >

Live Poll

Would you be willing to take a treatment injected only once every two months?

Most patients with schizophrenia surveyed in five countries said they would be willing to try a long-acting antipsychotic injection given only once every two months. The study, published in Patient Preferences and Adherence, drew on responses from adults with the condition in Canada, the United States, France, Germany and Italy.

Why it matters

Poor adherence to oral antipsychotic medication is common in schizophrenia, and long-acting options have been associated with better adherence and fewer relapses. Findings that patients favor less frequent dosing give clinicians and health systems evidence on what treatment formats patients may accept.

This survey-based study analyzed 212 participants with a mean age of 41.9 years, 53.3% of whom were women, using a 35-question online survey and a discrete choice experiment with 190 participants. Because the findings reflect stated preferences rather than observed treatment behavior, they indicate willingness rather than proven adherence.

The players

Patient Preferences and Adherence

A peer-reviewed journal that publishes research on patient preferences and treatment adherence across medical conditions.

The details

Participants completed an online survey about their treatment experience, and a subset completed a discrete choice experiment that asked them to weigh different treatment formats against one another. Treatment effectiveness and a reduction in hospital admissions were among the most important factors shaping preference and acceptance. Participants also showed a clear preference for less frequent administration, which is the core reason long-acting formats are being studied in this population.

Timeline

  1. Study published in 2026 in Patient Preferences and Adherence, volume 20.

Health Landscape

Long-acting injectable antipsychotics have been developed in response to the well-documented problem of poor adherence to daily oral medication in schizophrenia. This survey adds patient-side evidence that interest in even less frequent dosing may extend the reach of this treatment approach.

If you or someone you care for lives with schizophrenia, these findings suggest that longer-interval injectable options may be a format worth raising with a psychiatrist or prescribing clinician. Decisions about switching treatment formats are personal and are best made in conversation with your physician.

The takeaway

Most surveyed patients with schizophrenia were open to a once-every-2-months injection, and treatment effectiveness ranked highly in their choices. If treatment format is a concern for you, bring the question of less frequent options to your next appointment with your doctor.

Further reading

For related context on how long-term conditions shape treatment choices, explore our Autism coverage.

Source note: This article includes information reported by Psychiatry Advisor.

Live Poll

Would you be willing to take a treatment injected only once every two months?